Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Grants

Funding Acknowledgements

P Lorigan received consultancy and honoraria from Bristol Myer Squibb, Glaxosmithkline, Amgen, Novartis, Roche, Merck. J Larkin received institutional research support from MSD, Bristol Myer Squibb, Pfizer and Novartis; non-remunerated consultancy for Glaxosmithkline, Novartis, MSD, Bristol Myer Squibb, Pfizer and Roche/Genentech. G McArthur received research grant support from Pfizer, Celgene, Ventana; consultancy for Provectus; uncompensated consultancy for Pfizer, Millenium, Glaxosmithkline, Roche/Genentech, Novartis, Bristol Myer Squibb and Amgen. V Atkinson participated in an advisory committee for MSD; was a member of the advisory board for Bristol Myer Squibb; received honoraria from GSK and received travel support from GSK, BMS and Roche. M Millward received consultancy or advisory role to Roche, Bristol Myer Squibb, MSD and Glaxosmithkline; received research funding from Roche and Glaxosmithkline. S Ramanujam received travel and accommodation grants from Amgen. MC Andrews received travel support from Bristol Myer Squibb and MSD. J Cebon participated in advisory boards for Amgen and Merck. GV Long participated in advisory boards of Amgen, Bristol Myer Squibb, Glaxosmithkline, Novartis, Provectus, Roche and Merck Inc. MS Carlino participated in advisory boards for Merck, Amgen, Novartis and Bristol Myer Squibb. The remaining authors declare no conflict of interest.